Xencor, Inc. (XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for cancer and autoimmune diseases, has several upcoming catalysts to watch, including new data presentations at Digestive Disease Week (DDW) 2026, being held May 2-5, 2026, and multiple readouts and trial starts in the second half of 2026.
The company plans to present final results from its Phase 1 healthy-volunteer study of XmAb942, an extended half-life anti-TL1A antibody, at DDW 2026 in Chicago. Xencor will also share preclinical characterization data for XmAb412, a TL1A x IL23p19 bispecific antibody designed to target key inflammatory pathways in inflammatory bowel disease.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com